New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:53 EDTMYL, VRX, ENDP, PRGOPullback has created attractive pharma opportunities, says JPMorgan
JPMorgan believes nothing has fundamentally changed to warrant the recent pullback in the specialty pharmaceutical space and views the pullback as an attractive buying opportunity. JPMorgan named Endo Health (ENDP), Mylan (MYL), Perrigo (PRGO), and Valeant (VRX) as stocks on which it maintains Overweight ratings, citing their favorable positions given the wave of consolidation ongoing in the industry.
News For ENDP;MYL;PRGO;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 9, 2014
13:26 EDTVRXAckman's Allergan court win may prove costly down the road, Bloomberg says
When U.S. District Court Judge David Carter ruled on November 4 that Pershing Square can vote its 9.7% stake in Allergan (AGN) in a shareholder ballot aiming to remove Allergan directors, he also noted that there were “serious questions” regarding insider trading rules in the way Pershing Square acquired Allergan stock while preparing a bid with Valeant (VRX), says Bloomberg. Reference Link
November 7, 2014
17:05 EDTVRXValeant sends open letter to physician customers
Subscribe for More Information
14:56 EDTVRXAllergan says Valeant offers to date inadequate, would consider increased bid
Subscribe for More Information
10:00 EDTPRGOOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Overweight from Equalweight at Capital One... CA Technologies (CA) upgraded at Evercore ISI... CGG SA (CGG) upgraded to Hold from Sell at Canaccord... Cavium (CAVM) upgraded to Strong Buy from Outperform at Raymond James... Charter (CHTR) upgraded to Outperform from Market Perform at Raymond James... Chesapeake (CHK) upgraded to Overweight from Equal Weight at Johnson Rice... Container Store (TCS) upgraded at BofA/Merrill... Delhaize (DEG) upgraded to Neutral from Underperform at BofA/Merrill... Devon Energy (DVN) upgraded to Accumulate from Hold at Tudor Pickering... Dynegy (DYN) upgraded to Accumulate from Hold at Tudor Pickering... EOG Resources (EOG) upgraded to Buy from Accumulate at Tudor Pickering... Envestnet (ENV) upgraded at Raymond James... GNC Holdings (GNC) upgraded to Buy from Neutral at Goldman... Hospira (HSP) upgraded at Raymond James... Kinross Gold (KGC) upgraded to Buy from Neutral at UBS... Kosmos (KOS) upgraded at RBC Capital... Nationstar (NSM) upgraded to Market Perform from Underperform at Wells Fargo... Northern Oil and Gas (NOG) upgraded at Raymond James... Perrigo (PRGO) upgraded to Overweight from Equal Weight at Morgan Stanley... PetSmart (PETM) upgraded to Hold from Sell at Deutsche Bank... Plains GP Holdings (PAGP) upgraded at Credit Suisse... Rosetta Resources (ROSE) upgraded to Accumulate from Hold at Tudor Pickering... Splunk (SPLK) upgraded to Buy from Hold at Evercore ISI... Sunoco Logistics (SXL) upgraded to Buy from Neutral at UBS... Target (TGT) upgraded to Buy from Neutral at Cleveland Research... Walker & Dunlop (WD) upgraded to Outperform from Market Perform at Wells Fargo... XO Group (XOXO) upgraded to Buy from Neutral at B. Riley... Zynga (ZNGA) upgraded to Buy from Hold at Needham.
09:49 EDTVRXAckman says Allergan 'tipping scales' in Actavis’ favor, disadvantaging Valeant
Subscribe for More Information
08:21 EDTPRGOPerrigo upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
08:01 EDTMYLMylan signs alliance agreement with Disney Parks to enhance EpiPen access
Subscribe for More Information
07:57 EDTPRGOPerrigo upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
06:47 EDTPRGOPerrigo price target raised to $207 from $189 at Deutsche Bank
Deutsche Bank raised its price target for Perrigo shares to $207 citing the company's Q1 results and planned acquisition of Omega Pharma. Deutsche says the acquisition will accelerate Perrigo's expansion into the European over-the-counter market, which the firm calls "large and durable." It reiterates a Buy rating on Perrigo.
November 6, 2014
12:35 EDTPRGOPerrigo acquisition positive, says UBS
Subscribe for More Information
10:30 EDTVRXAllergan disclosure today forced by SEC, CNBC's Faber reports
Subscribe for More Information
09:28 EDTVRXActavis in active talks to acquire Allergan, Bloomberg reports
Actavis (ACT) is in active talks to acquire Allergan (AGN), Bloomberg reports, citing sources. Allergan earlier today disclosed in a filing that it has been approached by another party and that talks "may lead to negotiations." Shares of Allergan are up 1.1% to $198.50 in pre-open trading while Actavis is up 1% to $250.07. Valeant (VRX) is down 1.8% to $129.58. Reference Link
09:24 EDTVRXActavis in active talks to acquire Allergan, Bloomberg reports
Subscribe for More Information
09:06 EDTVRXAllergan says approach may lead to merger negotiations
Allergan (AGN) disclosed in new regulatory filing, “Notwithstanding the foregoing, we have been approached by another party regarding a potential merger transaction. Discussions between us and that party have continued and may lead to negotiations.” It has been reported that the unnamed party is Actavis (ACT). Allergan is attempting to fend off a hostile takeover by Valeant (VRX).
07:56 EDTPRGOPerrigo to host conference call
Subscribe for More Information
06:56 EDTPRGOPerrigo reinitiates shipments of Guaifenesin 600mg ER
Subscribe for More Information
06:38 EDTPRGOPerrigo backs FY15 adjusted EPS view of $7.20-$7.50, consensus $7.40
06:36 EDTPRGOPerrigo reports Q1 adjusted EPS $1.40, consensus $1.44
Subscribe for More Information
06:31 EDTPRGOPerrigo to acquire Omega Pharma NV for $4.5B
Subscribe for More Information
06:28 EDTPRGOPerrigo to acquire Omega Pharma NV for EUR 3.6B
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use